期刊文献+

硼替佐米治疗多发性骨髓瘤患者后出现急性肺损伤一例并文献复习 被引量:2

原文传递
导出
摘要 多发性骨髓瘤(MM)是一种以骨髓中积聚浆细胞为特征的恶性肿瘤,可导致骨质破坏和骨髓衰竭。目前尚无可以完全治愈MM的有效方法,但随着硼替佐米(Btz)、来那度胺等新药的应用及干细胞移植的广泛开展,MM患者的缓解率及总生存明显提高。其中,以硼替佐米为基础的多药联合治疗,是目前MM治疗的重要组成部分,被推荐用于一线治疗MM,对于进展性或复发性骨髓瘤的治疗总有效率亦可达60.5%。
出处 《中华临床医师杂志(电子版)》 CAS 2013年第19期156-157,共2页 Chinese Journal of Clinicians(Electronic Edition)
  • 相关文献

参考文献5

二级参考文献51

  • 1王亚非,邱录贵,邹德慧,王迎,邓书会,李园,徐燕,钱林生,赵耀中.硼替佐米治疗多发性骨髓瘤后严重肺损伤二例报告并文献复习[J].白血病.淋巴瘤,2008,17(2). 被引量:12
  • 2侯健,周帆,张永贞,景燕.硼替佐米治疗复发、难治性多发性骨髓瘤[J].中国新药与临床杂志,2005,24(7):579-581. 被引量:13
  • 3袁振刚,侯健,周帆,王东星,付卫军,陈玉宝,奚昊,杨盛玲.硼替佐米联合地塞米松治疗16例复发、难治性多发性骨髓瘤患者[J].中华血液学杂志,2006,27(10):653-655. 被引量:21
  • 4Dun X,Yuan Z,Fu W,et al.Severe pulmonary complications after bortezomib treatment in multiple myeloma.Hematol Oncol,2010,28:49-52.
  • 5Rajkumar SV,Richardson PG,Hideshima T,et al.Proteasome inhibition as a novel therapeutic target in human cancer.J Clin Onco1,2005,23:630-639.
  • 6Chauhan D,Hideshima T,Anderson KC.Proteasome inhibition in multiple myeloma:therapeutic implication.Annu Rev Pharmacol 0Toxico1,2005,45:465-476.
  • 7Schwartz MD,Moore EE,Moore FA,et al.Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome.Crit Care Med,1996,24:1285-1292.
  • 8Farver CF,Raychaudhuri B,Buhrow LT,et al.Constitutive NF-kappaB levels in human alveolar macrophages from normal volunteers.Cytokine,1998,10:868 -871.
  • 9Miyakoshi S,Kami M,Yuji K,et al.Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.Blood,2006,107:3492-3494.
  • 10Boyer JE,Batra RB,Ascensao JL,et al.Severe pulmonary complication after bortezomib treatment for multiple myeloma.Blood,2006,108:1113.

共引文献41

同被引文献14

  • 1王亚非,邱录贵,邹德慧,王迎,邓书会,李园,徐燕,钱林生,赵耀中.硼替佐米治疗多发性骨髓瘤后严重肺损伤二例报告并文献复习[J].白血病.淋巴瘤,2008,17(2). 被引量:12
  • 2急性肺损伤/急性呼吸窘迫综合征诊断和治疗指南(2006)[J].中国实用外科杂志,2007,27(1):1-6. 被引量:196
  • 3Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication [ J ]. Annu Rev Phar-maeol Toxicol, 2005,45:465 -476.
  • 4Fujisawa M, Suehara Y, Fukumoto K, et al. Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20 years [ J ]. Ann Hematol, 2015,84(689) :1 - 10.
  • 5Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma [ J]. N Engl J Med, 2003,348(26) :2609 -2617.
  • 6Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complica- tions in Japanese patients after bortezomib treatment for refractory multiple myeloma [ J ]. Blood, 2006,107 ( 9 ) : 3492 - 3494.
  • 7Min CK, Lee S, Kim YJ, et al. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; associ- ation with pro - inflammatory cytokines [ J ]. Eur J Haematol, 2006,76(3 ) :265 - 268.
  • 8Pitini V, Arrigo C, Ahavilla G, et al. Severe pulmonary compli- cations after bortezomib treatment for multiple myeloma: an un- recognized pulmonary vasculitis? [ J]. Leuk Res, 2007,31 (7) : 1027 - 1028.
  • 9顿晓熠,袁振刚,傅卫军,侯健.硼替佐米治疗多发性骨髓瘤致五例患者严重肺损伤[J].中华血液学杂志,2010,31(4):259-261. 被引量:9
  • 10魏永强,刘启发,张钰,孙竞,孟凡义.硼替佐米治疗多发性骨髓瘤致肺损伤1例并文献复习[J].南方医科大学学报,2010,30(5):1177-1179. 被引量:1

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部